Moderna Inc. (MRNA)
42.30
-2.02%
At close: Jan 10, 2025, 3:58 PM
42.38
0.18%
After-hours Jan 10, 2025, 07:43 PM EST
undefined% (undefined)
| Bid | 42.23 |
| Market Cap | 16.28B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -5.81 |
| PE Ratio (ttm) | -7.28 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 42.39 |
| Volume | 5,440,221 |
| Avg. Volume (20D) | 8,220,850 |
| Open | 42.77 |
| Previous Close | 43.17 |
| Day's Range | 41.78 - 43.70 |
| 52-Week Range | 35.80 - 170.47 |
| Beta | undefined |
About MRNA
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 7, 2018
Employees 5,600
Stock Exchange NASDAQ
Ticker Symbol MRNA
Website https://www.modernatx.com
Analyst Forecast
According to 18 analyst ratings, the average rating for MRNA stock is "Hold." The 12-month stock price forecast is $69, which is an increase of 63.10% from the latest price.
Buy 27.78%
Hold 55.56%
Sell 16.67%
Next Earnings Release
Moderna Inc. is scheduled to release its earnings on Feb 20, 2025,
before market opens.
Analysts project revenue of $1.57B, reflecting a -44.15% YoY shrinking and earnings per share of -1.46, making a -365.45% decrease YoY.
Analysts project revenue of $1.57B, reflecting a -44.15% YoY shrinking and earnings per share of -1.46, making a -365.45% decrease YoY.
Past Earnings Volatility
The average price volatility over this 3-day period is
... Unlock content with
Pro Subscription
4 days ago ·
Source
-9.17%
Moderna shares are trading lower after UBS cut its...
Unlock content with
Pro Subscription
5 days ago ·
Source
+11.65%
Shares of vaccine makers are trading higher after the first bird flu death was reporting in the US. Additionally, a recent CDC report noted an increase in acute respiratory illness activity.
